Sirtuin Pipeline

Sirtris is focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases, such as Type 2 Diabetes, and various forms of cancer, as well as mitochondrial, inflammatory, neurodegenerative and cardiovascular diseases.

Pipeline Highlights:

• SRT501, a formulation of resveratrol with roughly five times higher bioavailability than the chemical alone
  • Two completed 28-day Phase IIa studies in Type 2 Diabetes show safety, lowering fasting plasma glucose and insulin, and a significant lowering of glucose in an oral glucose tolerance test at the two hour time point.
  • Completing a 3-month Phase IIa trial in patients with Type 2 Diabetes who remain uncontrolled despite metformin therapy
  • Currently under way with a Phase IIa trial in oncology
    
    
• SRT2104, a new chemical entity (NCE) that activates SIRT1 – structurally unrelated to and up to 1,000 times more potent than resveratrol
  • Completed a first-in-human Phase I trial to assess safety, tolerability, and pharmacokinetics
  • Will enter into a Phase IIa human trial in 2009